Cardarine vs MK-2866
Limited Research vs Moderate Research
compatible Researched · 90% Cardarine (GW-501516) is a PPAR-delta agonist that enhances fatty acid oxidation and endurance without interacting with the androgen receptor. It does not contribute to HPTA suppression, making it a common addition to MK-2866 cycles targeting body recomposition or cutting goals.
Molecular Data
Cardarine MK-2866
Weight 453.50 Da 389.33 Da
Half-life ~16-24 hours ~24 hours
Type PPAR-delta agonist (C21H18F3NO3S2) Non-steroidal selective androgen receptor modulator (C19H14F3N3O3)
Key Benefits
Cardarine
01 Dramatic increase in endurance capacity through enhanced fatty acid oxidation in skeletal muscle
02 Promotes fat loss by shifting metabolic fuel preference toward fatty acid utilization over glucose
03 Improves lipid profiles: increases HDL cholesterol, decreases LDL cholesterol, and lowers triglycerides
04 Non-hormonal mechanism -- does not suppress testosterone or require post-cycle therapy
05 No androgenic side effects (no hair loss, no prostate stimulation, no virilization in women)
06 Long half-life (16-24 hours) permits convenient once-daily oral dosing
07 May offset lipid disruption caused by SARMs or anabolic steroids when used in combination
MK-2866
01 Increases lean body mass in a dose-dependent manner with clinical trial support
02 Preserves muscle mass during caloric deficit or catabolic conditions
03 Selective tissue activity reduces androgenic side effects compared to anabolic steroids
04 Oral bioavailability eliminates the need for injections
05 Does not aromatize to estrogen, avoiding gynecomastia and water retention
06 Improves physical function and stair-climbing power in clinical populations
07 Long 24-hour half-life allows convenient once-daily dosing
08 Mild side effect profile at commonly studied doses
Side Effects
Cardarine
Headaches (typically transient, most common in the first week)
Mild gastrointestinal discomfort (nausea, loose stools, or stomach upset, usually dose-dependent and transient)
MK-2866
Mild testosterone suppression (dose-dependent, typically 10-30% reduction at 25 mg)
HDL cholesterol reduction (10-20% suppression observed in clinical trials)
Headaches, particularly during the first 1-2 weeks
Mild back pain or muscle cramps
Transient fatigue toward the end of longer cycles
Slight reduction in libido at higher doses or extended cycle lengths
Contraindications
Personal or family history of cancer (the rodent carcinogenicity data warrants extreme caution in individuals with elevated cancer risk)
Pregnancy or potential pregnancy
Breastfeeding
Pre-existing liver disease (limited safety data)
Individuals under 18 years of age
Active liver disease or significantly elevated liver enzymes
Hormone-sensitive cancers (breast, prostate) without oncologist clearance
Pregnancy or breastfeeding (potential endocrine disruption to fetus/infant)
Individuals under 21 years of age (risk of premature HPTA disruption during development)
Concurrent use of hepatotoxic medications without liver function monitoring
Known hypersensitivity to MK-2866 or any formulation excipients
Competitive athletes subject to WADA or USADA anti-doping testing
Research Evidence
Cardarine MK-2866
Status Limited Research Moderate Research
References 5 studies 5 studies
Latest May 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.